William Blair Forecasts Increased Earnings for 908 Devices

908 Devices Inc. (NASDAQ:MASS) – Equities research analysts at William Blair lifted their Q2 2025 EPS estimates for 908 Devices in a research note issued to investors on Wednesday, May 14th. William Blair analyst M. Larew now forecasts that the company will post earnings of ($0.13) per share for the quarter, up from their prior estimate of ($0.18). The consensus estimate for 908 Devices’ current full-year earnings is ($1.99) per share. William Blair also issued estimates for 908 Devices’ Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.07) EPS, Q1 2026 earnings at ($0.11) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.03) EPS and FY2026 earnings at ($0.28) EPS.

908 Devices (NASDAQ:MASS) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.05. 908 Devices had a negative return on equity of 24.60% and a negative net margin of 109.11%. The company had revenue of $11.78 million for the quarter, compared to analyst estimates of $11.90 million.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of 908 Devices in a report on Saturday, May 10th. Two equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, 908 Devices presently has an average rating of “Moderate Buy” and a consensus price target of $5.33.

908 Devices Price Performance

NASDAQ:MASS opened at $4.94 on Monday. The company’s 50-day moving average is $4.62 and its two-hundred day moving average is $3.29. 908 Devices has a 1-year low of $1.81 and a 1-year high of $6.86. The firm has a market capitalization of $177.15 million, a price-to-earnings ratio of -2.79 and a beta of 0.26.

Institutional Investors Weigh In On 908 Devices

Several large investors have recently bought and sold shares of MASS. Two Sigma Advisers LP purchased a new position in shares of 908 Devices in the 4th quarter valued at about $30,000. CWM LLC boosted its holdings in 908 Devices by 541.2% in the first quarter. CWM LLC now owns 6,963 shares of the company’s stock valued at $31,000 after purchasing an additional 5,877 shares in the last quarter. Prudential Financial Inc. purchased a new position in 908 Devices in the fourth quarter valued at approximately $34,000. Occudo Quantitative Strategies LP acquired a new stake in 908 Devices during the fourth quarter worth approximately $36,000. Finally, Two Sigma Investments LP acquired a new stake in 908 Devices during the fourth quarter worth approximately $42,000. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Insider Buying and Selling at 908 Devices

In other news, Director Mark Spoto bought 10,000 shares of the business’s stock in a transaction on Wednesday, May 14th. The shares were bought at an average price of $4.29 per share, with a total value of $42,900.00. Following the completion of the transaction, the director now directly owns 62,971 shares in the company, valued at $270,145.59. This trade represents a 18.88% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 27.70% of the company’s stock.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.